United Therapeutics(US:UTHR)2021-05-05 17:55Financial Data and Key Metrics Changes - The company aims to increase the number of patients treated from over 8,000 to over 25,000 by 2025, a goal referred to as "25/25" [8][25] - The company expects to achieve approximately half of the required growth from WHO Group 1 pulmonary arterial hypertension and the other half from WHO Group 3 pulmonary hypertension [10][15] Business Line Data and Key Metrics Changes - The company anticipates gaining about 3,000 new patients each from Remodulin, Tyvaso, and Orenitram in the WHO Group 1 category [11][12][13] - The company is the only drug approved for the IPF market segment of patients with pulmonary hypertension, targeting to capture at least 9,000 patients from this group by 2025 [17] Market Data and Key Metrics Changes - There are approximately 50,000 patients being treated for pulmonary hypertension in the U.S., with about 45,000 treated with non-United Therapeutics drugs, indicating a significant market opportunity [14] - The company is focusing on educating new treaters and engaging patients to increase treatment uptake for Tyvaso in the ILD-PH segment [36] Company Strategy and Development Direction - The company is focused on expanding its patient base significantly by leveraging new product approvals and enhancing treatment options [25] - The company has several late-phase clinical trials underway, including studies for Tyvaso in COPD-associated pulmonary hypertension and ralinepag in Group 1 pulmonary hypertension [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in the pulmonary hypertension market, citing a meaningful unmet need and the company's capabilities to address it [25][62] - The management believes that the goal of treating 25,000 patients by 2025 is realistic given the annual progression rates of existing patients [62] Other Important Information - The company is developing a once-daily formulation of Orenitram and less painful forms of Remodulin, expected to launch by 2025 [24] - The company is actively building relationships with new treaters and educating them about the benefits of Tyvaso [35] Q&A Session Summary Question: Strategy for Group 3 PH-ILD and patient targeting - Management indicated that they are building relationships with ILD treaters and have ongoing patient engagement efforts to educate patients about Tyvaso [30][36] Question: Commercialization plans for Tyvaso solution vs. Tyvaso DPI - Management stated that they expect a significant number of patients to transition to the dry powder inhaler, estimating a 70-30 split between dry powder and nebulizer usage [41] Question: Growth trajectory of Orenitram post-FREEDOM-EV study - Management noted that they are seeing an uptick in referrals and starts for Orenitram, with ongoing efforts to educate physicians on its value proposition [46][50] Question: TETON program and potential for DPI studies - Management confirmed that once approvals are received for Tyvaso, additional indications for DPI will follow, and they are studying patient preferences for delivery methods [57]